Pyxis Oncology (PYXS) Revenue (2024 - 2025)
Pyxis Oncology's (PYXS) quarterly Revenue came in at $11.0 million in Q4 2025, up 291.42% quarter-over-quarter from $2.8 million in Q2 2025.
Powered by 
Analysis
Pyxis Oncology (PYXS) Revenue (2024 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has reported Revenue for 2 consecutive years, with $11.0 million the latest figure, recorded in Q4 2025.
- On a quarterly basis, Revenue changed N/A year-over-year to $11.0 million in Q4 2025; TTM through Jun 2026 was $13.9 million, a 391.42% increase from a year earlier, with the FY2025 full-year figure at $13.9 million, down 14.17% from the prior year.
- Revenue was $11.0 million for Q4 2025 at Pyxis Oncology, up from $2.8 million in the prior quarter.
- Over five years, Revenue peaked at $16.1 million in Q1 2024 and troughed at $2.8 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.64 Bn | 192.65 Bn | 7.24 Bn | 10.05 Bn |
| 2 | Gilead Sciences | 179.82 Bn | 176.65 Bn | 6.22 Bn | 7.80 Bn |
| 3 | Vertex Pharmaceuticals | 131.16 Bn | 123.31 Bn | 2.84 Bn | 3.33 Bn |
| 4 | Regeneron Pharmaceuticals | 81.67 Bn | 73.67 Bn | 3.93 Bn | 4.29 Bn |
| 5 | Argenx Se | 60.28 Bn | 55.09 Bn | 1.37 Bn | 1.52 Bn |
| 6 | Moderna | 53.91 Bn | 48.77 Bn | 52.00 Mn | 145.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.12 Bn | 29.81 Bn | 992.69 Mn | 1.29 Bn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 2.74 Bn |
| 9 | Roivant Sciences | 29.05 Bn | 29.05 Bn | 1.16 Mn | 1.44 Mn |
| 10 | Pyxis Oncology | 210.21 Mn | 177.22 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 11.04 Mn |
| Jun 30, 2025 | 2.82 Mn |
| Mar 31, 2024 | 16.15 Mn |